Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders

Clinical trial NCT02210858 · COMPLETED

Trial details

NCT number: NCT02210858
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Accelerated Phase of Disease Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Chronic Phase of Disease Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Recurrent Disease

Start date: 2000-05-01
Primary completion: 2004-11-12
Enrollment: 31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.